Bard Financial Services Inc. lessened its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 3.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 85,390 shares of the company’s stock after selling 3,500 shares during the quarter. Novo Nordisk A/S accounts for approximately 0.9% of Bard Financial Services Inc.’s holdings, making the stock its 28th largest holding. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $7,345,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $25,000. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Abound Wealth Management raised its stake in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $42,000. Finally, Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S in the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have commented on NVO. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.20.
Novo Nordisk A/S Price Performance
Shares of NYSE NVO traded down $2.60 during trading on Monday, hitting $85.05. The company had a trading volume of 6,088,233 shares, compared to its average volume of 4,615,631. The stock has a fifty day simple moving average of $103.06 and a two-hundred day simple moving average of $121.08. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The firm has a market capitalization of $381.66 billion, a price-to-earnings ratio of 27.52, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- Roth IRA Calculator: Calculate Your Potential Returns
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- How to Choose Top Rated Stocks
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- How to Calculate Options Profits
- How Cigna Remains at the Top of the Health Insurance Food Chain
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.